Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BeOne Medicines Ltd.ONC · Entity 2168 | Director · Chief Executive Officer | August 10, 2026 | August 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BeOne Medicines Ltd.
Report date August 10, 2026 · Filed August 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| American Depositary SharesSEC Table I · non-derivative | Direct | 0 |
Last balance in matching sequence
After 2026-08-12 transaction · row 30
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
24 source rowsRow 7 · 2026-08-10 · Sale · Disposed 67 · Balance 240,743 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. Row 8 · 2026-08-10 · Sale · Disposed 2,813 · Balance 237,930 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $351.01 to $351.99, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 9 · 2026-08-10 · Sale · Disposed 3,673 · Balance 234,257 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $353.00 to $353.99, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 10 · 2026-08-10 · Sale · Disposed 6,717 · Balance 227,540 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $354.03 to $355.01, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 11 · 2026-08-10 · Sale · Disposed 3,476 · Balance 224,064 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $355.08 to $356.05, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 12 · 2026-08-10 · Sale · Disposed 12,418 · Balance 211,646 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F12: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $356.08 to $357.06, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 13 · 2026-08-10 · Sale · Disposed 15,869 · Balance 195,777 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F13: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $357.08 to $358.07, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 14 · 2026-08-10 · Sale · Disposed 45,044 · Balance 150,733 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F14: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $358.08 to $359.07, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 15 · 2026-08-10 · Sale · Disposed 21,254 · Balance 129,479 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F15: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $359.08 to $360.00, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 16 · 2026-08-10 · Sale · Disposed 3,680 · Balance 125,799 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F16: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $360.25 to $361.14, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 17 · 2026-08-11 · Sale · Disposed 13,695 · Balance 112,104 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F17: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $358.90 to $359.89, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 18 · 2026-08-11 · Sale · Disposed 8,081 · Balance 104,023 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F18: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $359.92 to $360.91, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 19 · 2026-08-11 · Sale · Disposed 14,569 · Balance 89,454 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F19: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $360.92 to $361.91, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 20 · 2026-08-11 · Sale · Disposed 11,568 · Balance 77,886 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F20: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $361.94 to $362.74, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 21 · 2026-08-11 · Sale · Disposed 13,403 · Balance 64,483 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F21: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $362.95 to $363.94, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 22 · 2026-08-11 · Sale · Disposed 5,211 · Balance 59,272 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F22: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $363.95 to $364.90, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 23 · 2026-08-11 · Sale · Disposed 3,176 · Balance 56,096 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F23: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $365.00 to $365.90, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 24 · 2026-08-11 · Sale · Disposed 1,200 · Balance 54,896 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F24: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $366.00 to $366.99, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 25 · 2026-08-11 · Sale · Disposed 4 · Balance 54,892 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. Row 26 · 2026-08-12 · Sale · Disposed 1,980 · Balance 52,912 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F25: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $354.35 to $355.05, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 27 · 2026-08-12 · Sale · Disposed 2,515 · Balance 50,397 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F26: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $355.92 to $356.91, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 28 · 2026-08-12 · Sale · Disposed 15,396 · Balance 35,001 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F27: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $356.95 to $357.94, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 29 · 2026-08-12 · Sale · Disposed 20,899 · Balance 14,102 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F28: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $357.95 to $358.94, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 30 · 2026-08-12 · Sale · Disposed 14,102 · Balance 0 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F29: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $358.95 to $359.68, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 1,330,988 |
Reported balance
Holding disclosure · report date 2026-08-10 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,330,988 |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Footnote | 481,533 |
Reported balance
Holding disclosure · report date 2026-08-10 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 481,533 F1: These securities are held by the P&O Trust, the beneficiaries of which include the Reporting Person's child and others, for which the Reporting Person disclaims beneficial ownership. |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Footnote | 7,699,158 |
Reported balance
Holding disclosure · report date 2026-08-10 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 7,699,158 F2: These securities are held in a grantor retained annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership. |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Footnote | 28,204,115 |
Reported balance
Holding disclosure · report date 2026-08-10 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 28,204,115 F3: These securities are held by Oyler Investment LLC, of which 99% of the limited liability company interests are owned by a grantor retain annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership. |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Footnote | 9,545,000 |
Reported balance
Holding disclosure · report date 2026-08-10 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 9,545,000 F4: These securities are held for the benefit of the Reporting Person in a Roth IRA PENSCO trust account. |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Footnote | 102,188 |
Reported balance
Holding disclosure · report date 2026-08-10 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 102,188 F5: These securities are held by The John Oyler Legacy Trust for the benefit of the Reporting Person's child, for which the Reporting Person disclaims beneficial ownership. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities are held by the P&O Trust, the beneficiaries of which include the Reporting Person's child and others, for which the Reporting Person disclaims beneficial ownership.
F2: These securities are held in a grantor retained annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership.
F3: These securities are held by Oyler Investment LLC, of which 99% of the limited liability company interests are owned by a grantor retain annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership.
F4: These securities are held for the benefit of the Reporting Person in a Roth IRA PENSCO trust account.
F5: These securities are held by The John Oyler Legacy Trust for the benefit of the Reporting Person's child, for which the Reporting Person disclaims beneficial ownership.
F6: Each American Depositary Share represents 13 Ordinary Shares.
F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026.
F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $351.01 to $351.99, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $353.00 to $353.99, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $354.03 to $355.01, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $355.08 to $356.05, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F12: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $356.08 to $357.06, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F13: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $357.08 to $358.07, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F14: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $358.08 to $359.07, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F15: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $359.08 to $360.00, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F16: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $360.25 to $361.14, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F17: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $358.90 to $359.89, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F18: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $359.92 to $360.91, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F19: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $360.92 to $361.91, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F20: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $361.94 to $362.74, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F21: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $362.95 to $363.94, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F22: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $363.95 to $364.90, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F23: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $365.00 to $365.90, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F24: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $366.00 to $366.99, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F25: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $354.35 to $355.05, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F26: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $355.92 to $356.91, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F27: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $356.95 to $357.94, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F28: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $357.95 to $358.94, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F29: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $358.95 to $359.68, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 27, 2022 Filed Dec 29, 2022 23:24 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 1,119 | $224.29 | $250,984.43 |
DisclosureSEC source: 0001651308-22-000236 · wf-form4_167235627748165.xml · nonDerivative · entry 9 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F6 · security: Each American Depositary Share represents 13 Ordinary Shares. F9 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on March 7, 2022. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $224.00 to $224.76, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. F4 · ownership.nature: These securities are held for the benefit of the Reporting Person in a Roth IRA PENSCO trust account. Read SEC document |
| December 27, 2022 Filed Dec 29, 2022 23:24 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 1,120 | $224.29 | $251,208.83 |
DisclosureSEC source: 0001651308-22-000236 · wf-form4_167235627748165.xml · nonDerivative · entry 8 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F6 · security: Each American Depositary Share represents 13 Ordinary Shares. F9 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on March 7, 2022. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $224.00 to $224.76, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. F3 · ownership.nature: These securities are held by Oyler Investment LLC, of which 99% of the limited liability company interest is owned by a grantor retained annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership. Read SEC document |
| December 27, 2022 Filed Dec 29, 2022 23:24 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 1,120 | $224.29 | $251,208.61 |
DisclosureSEC source: 0001651308-22-000236 · wf-form4_167235627748165.xml · nonDerivative · entry 7 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F6 · security: Each American Depositary Share represents 13 Ordinary Shares. F7 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 13, 2022. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $224.00 to $224.76, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 22:10 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 100 | $210.18 | $21,018.00 |
DisclosureSEC source: 0001651308-22-000210 · wf-form4_166872298723964.xml · nonDerivative · entry 19 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F6 · security: Each American Depositary Share represents 13 Ordinary Shares. F15 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on March 8, 2022. F1 · ownership.nature: These securities are held by the P&O Trust, the beneficiaries of which include the Reporting Person's child and others, for which the Reporting Person disclaims beneficial ownership. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 22:10 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 1,400 | $208.45 | $291,823.98 |
DisclosureSEC source: 0001651308-22-000210 · wf-form4_166872298723964.xml · nonDerivative · entry 18 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 100 F6 · security: Each American Depositary Share represents 13 Ordinary Shares. F15 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on March 8, 2022. F20 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $208.07 to $208.95, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. F1 · ownership.nature: These securities are held by the P&O Trust, the beneficiaries of which include the Reporting Person's child and others, for which the Reporting Person disclaims beneficial ownership. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 22:10 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 835 | $207.62 | $173,364.37 |
DisclosureSEC source: 0001651308-22-000210 · wf-form4_166872298723964.xml · nonDerivative · entry 17 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,500 F6 · security: Each American Depositary Share represents 13 Ordinary Shares. F15 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on March 8, 2022. F19 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $207.00 to $207.97, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. F1 · ownership.nature: These securities are held by the P&O Trust, the beneficiaries of which include the Reporting Person's child and others, for which the Reporting Person disclaims beneficial ownership. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 22:10 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 1,009 | $206.51 | $208,371.52 |
DisclosureSEC source: 0001651308-22-000210 · wf-form4_166872298723964.xml · nonDerivative · entry 16 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,335 F6 · security: Each American Depositary Share represents 13 Ordinary Shares. F15 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on March 8, 2022. F18 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $206.00 to $206.99, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. F1 · ownership.nature: These securities are held by the P&O Trust, the beneficiaries of which include the Reporting Person's child and others, for which the Reporting Person disclaims beneficial ownership. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 22:10 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 884 | $205.52 | $181,682.69 |
DisclosureSEC source: 0001651308-22-000210 · wf-form4_166872298723964.xml · nonDerivative · entry 15 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,344 F6 · security: Each American Depositary Share represents 13 Ordinary Shares. F15 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on March 8, 2022. F17 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $205.00 to $205.93, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. F1 · ownership.nature: These securities are held by the P&O Trust, the beneficiaries of which include the Reporting Person's child and others, for which the Reporting Person disclaims beneficial ownership. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 22:10 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 700 | $204.24 | $142,968.21 |
DisclosureSEC source: 0001651308-22-000210 · wf-form4_166872298723964.xml · nonDerivative · entry 14 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,228 F6 · security: Each American Depositary Share represents 13 Ordinary Shares. F15 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on March 8, 2022. F16 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $203.93 to $204.67, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. F1 · ownership.nature: These securities are held by the P&O Trust, the beneficiaries of which include the Reporting Person's child and others, for which the Reporting Person disclaims beneficial ownership. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 22:10 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 600 | $209.88 | $125,929.02 |
DisclosureSEC source: 0001651308-22-000210 · wf-form4_166872298723964.xml · nonDerivative · entry 13 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F6 · security: Each American Depositary Share represents 13 Ordinary Shares. F7 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 13, 2022. F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $209.41 to $210.13, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 22:10 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 4,487 | $208.55 | $935,755.77 |
DisclosureSEC source: 0001651308-22-000210 · wf-form4_166872298723964.xml · nonDerivative · entry 12 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600 F6 · security: Each American Depositary Share represents 13 Ordinary Shares. F7 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 13, 2022. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $208.12 to $209.05, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 22:10 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 7,643 | $207.66 | $1,587,162.19 |
DisclosureSEC source: 0001651308-22-000210 · wf-form4_166872298723964.xml · nonDerivative · entry 11 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,087 F6 · security: Each American Depositary Share represents 13 Ordinary Shares. F7 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 13, 2022. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $207.11 to $208.10, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 22:10 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 4,456 | $206.57 | $920,476.37 |
DisclosureSEC source: 0001651308-22-000210 · wf-form4_166872298723964.xml · nonDerivative · entry 10 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,730 F6 · security: Each American Depositary Share represents 13 Ordinary Shares. F7 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 13, 2022. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $206.11 to $207.08, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 22:10 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 4,081 | $205.67 | $839,353.96 |
DisclosureSEC source: 0001651308-22-000210 · wf-form4_166872298723964.xml · nonDerivative · entry 9 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,186 F6 · security: Each American Depositary Share represents 13 Ordinary Shares. F7 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 13, 2022. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $205.11 to $206.10, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 22:10 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 2,333 | $204.60 | $477,334.13 |
DisclosureSEC source: 0001651308-22-000210 · wf-form4_166872298723964.xml · nonDerivative · entry 8 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,267 F6 · security: Each American Depositary Share represents 13 Ordinary Shares. F7 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 13, 2022. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $204.11 to $205.10, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 22:10 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 1,400 | $203.64 | $285,093.62 |
DisclosureSEC source: 0001651308-22-000210 · wf-form4_166872298723964.xml · nonDerivative · entry 7 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,600 F6 · security: Each American Depositary Share represents 13 Ordinary Shares. F7 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 13, 2022. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $203.01 to $203.99, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| September 21, 2022 Filed Sep 22, 2022 21:34 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 450 | $153.12 | $68,903.01 |
DisclosureSEC source: 0001651308-22-000177 · wf-form4_166388243470166.xml · nonDerivative · entry 24 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F6 · security: Each American Depositary Share represents 13 Ordinary Shares. F7 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on March 7, 2022. F16 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.885 to $153.40, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. F4 · ownership.nature: These securities are held for the benefit of the Reporting Person in a Roth IRA PENSCO trust account. Read SEC document |
| September 21, 2022 Filed Sep 22, 2022 21:34 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 500 | $152.35 | $76,174.50 |
DisclosureSEC source: 0001651308-22-000177 · wf-form4_166388243470166.xml · nonDerivative · entry 23 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 450 F6 · security: Each American Depositary Share represents 13 Ordinary Shares. F7 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on March 7, 2022. F15 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.84 to $152.82, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. F4 · ownership.nature: These securities are held for the benefit of the Reporting Person in a Roth IRA PENSCO trust account. Read SEC document |
| September 21, 2022 Filed Sep 22, 2022 21:34 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 1,716 | $151.16 | $259,396.22 |
DisclosureSEC source: 0001651308-22-000177 · wf-form4_166388243470166.xml · nonDerivative · entry 22 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 950 F6 · security: Each American Depositary Share represents 13 Ordinary Shares. F7 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on March 7, 2022. F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.81 to $151.63, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. F4 · ownership.nature: These securities are held for the benefit of the Reporting Person in a Roth IRA PENSCO trust account. Read SEC document |
| September 21, 2022 Filed Sep 22, 2022 21:34 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 2,436 | $150.35 | $366,260.40 |
DisclosureSEC source: 0001651308-22-000177 · wf-form4_166388243470166.xml · nonDerivative · entry 21 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,666 F6 · security: Each American Depositary Share represents 13 Ordinary Shares. F7 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on March 7, 2022. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.81 to $150.79, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. F4 · ownership.nature: These securities are held for the benefit of the Reporting Person in a Roth IRA PENSCO trust account. Read SEC document |
| September 21, 2022 Filed Sep 22, 2022 21:34 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 2,638 | $149.21 | $393,621.52 |
DisclosureSEC source: 0001651308-22-000177 · wf-form4_166388243470166.xml · nonDerivative · entry 20 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,102 F6 · security: Each American Depositary Share represents 13 Ordinary Shares. F7 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on March 7, 2022. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.81 to $149.79, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. F4 · ownership.nature: These securities are held for the benefit of the Reporting Person in a Roth IRA PENSCO trust account. Read SEC document |
| September 21, 2022 Filed Sep 22, 2022 21:34 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 2,000 | $148.25 | $296,502.40 |
DisclosureSEC source: 0001651308-22-000177 · wf-form4_166388243470166.xml · nonDerivative · entry 19 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,740 F6 · security: Each American Depositary Share represents 13 Ordinary Shares. F7 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on March 7, 2022. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.81 to $148.72, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. F4 · ownership.nature: These securities are held for the benefit of the Reporting Person in a Roth IRA PENSCO trust account. Read SEC document |
| September 21, 2022 Filed Sep 22, 2022 21:34 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 450 | $153.12 | $68,903.01 |
DisclosureSEC source: 0001651308-22-000177 · wf-form4_166388243470166.xml · nonDerivative · entry 18 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F6 · security: Each American Depositary Share represents 13 Ordinary Shares. F7 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on March 7, 2022. F16 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.885 to $153.40, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. F3 · ownership.nature: These securities are held by Oyler Investment LLC, of which 99% of the limited liability company interest is owned by a grantor retained annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership. Read SEC document |
| September 21, 2022 Filed Sep 22, 2022 21:34 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 500 | $152.35 | $76,174.50 |
DisclosureSEC source: 0001651308-22-000177 · wf-form4_166388243470166.xml · nonDerivative · entry 17 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 450 F6 · security: Each American Depositary Share represents 13 Ordinary Shares. F7 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on March 7, 2022. F15 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.84 to $152.82, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. F3 · ownership.nature: These securities are held by Oyler Investment LLC, of which 99% of the limited liability company interest is owned by a grantor retained annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership. Read SEC document |
| September 21, 2022 Filed Sep 22, 2022 21:34 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 1,716 | $151.16 | $259,395.71 |
DisclosureSEC source: 0001651308-22-000177 · wf-form4_166388243470166.xml · nonDerivative · entry 16 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 950 F6 · security: Each American Depositary Share represents 13 Ordinary Shares. F7 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on March 7, 2022. F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.81 to $151.63, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. F3 · ownership.nature: These securities are held by Oyler Investment LLC, of which 99% of the limited liability company interest is owned by a grantor retained annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership. Read SEC document |
| September 21, 2022 Filed Sep 22, 2022 21:34 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 2,435 | $150.35 | $366,110.04 |
DisclosureSEC source: 0001651308-22-000177 · wf-form4_166388243470166.xml · nonDerivative · entry 15 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,666 F6 · security: Each American Depositary Share represents 13 Ordinary Shares. F7 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on March 7, 2022. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.81 to $150.79, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. F3 · ownership.nature: These securities are held by Oyler Investment LLC, of which 99% of the limited liability company interest is owned by a grantor retained annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership. Read SEC document |
| September 21, 2022 Filed Sep 22, 2022 21:34 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 2,639 | $149.21 | $393,771.00 |
DisclosureSEC source: 0001651308-22-000177 · wf-form4_166388243470166.xml · nonDerivative · entry 14 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,101 F6 · security: Each American Depositary Share represents 13 Ordinary Shares. F7 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on March 7, 2022. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.81 to $149.79, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. F3 · ownership.nature: These securities are held by Oyler Investment LLC, of which 99% of the limited liability company interest is owned by a grantor retained annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership. Read SEC document |
| September 21, 2022 Filed Sep 22, 2022 21:34 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 2,000 | $148.25 | $296,502.00 |
DisclosureSEC source: 0001651308-22-000177 · wf-form4_166388243470166.xml · nonDerivative · entry 13 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,740 F6 · security: Each American Depositary Share represents 13 Ordinary Shares. F7 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on March 7, 2022. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.81 to $148.72, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. F3 · ownership.nature: These securities are held by Oyler Investment LLC, of which 99% of the limited liability company interest is owned by a grantor retained annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership. Read SEC document |
| September 20, 2022 Filed Sep 22, 2022 21:34 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 100 | $154.77 | $15,477.00 |
DisclosureSEC source: 0001651308-22-000177 · wf-form4_166388243470166.xml · nonDerivative · entry 12 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F6 · security: Each American Depositary Share represents 13 Ordinary Shares. F7 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on March 7, 2022. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $154.69 to $154.85, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. F4 · ownership.nature: These securities are held for the benefit of the Reporting Person in a Roth IRA PENSCO trust account. Read SEC document |
| September 20, 2022 Filed Sep 22, 2022 21:34 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 5,412 | $153.81 | $832,396.45 |
DisclosureSEC source: 0001651308-22-000177 · wf-form4_166388243470166.xml · nonDerivative · entry 11 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 100 F6 · security: Each American Depositary Share represents 13 Ordinary Shares. F7 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on March 7, 2022. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.56 to $154.39, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. F4 · ownership.nature: These securities are held for the benefit of the Reporting Person in a Roth IRA PENSCO trust account. Read SEC document |
| September 20, 2022 Filed Sep 22, 2022 21:34 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 9,748 | $153.32 | $1,494,547.76 |
DisclosureSEC source: 0001651308-22-000177 · wf-form4_166388243470166.xml · nonDerivative · entry 10 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,512 F6 · security: Each American Depositary Share represents 13 Ordinary Shares. F7 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on March 7, 2022. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.56 to $153.55, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. F4 · ownership.nature: These securities are held for the benefit of the Reporting Person in a Roth IRA PENSCO trust account. Read SEC document |
| September 20, 2022 Filed Sep 22, 2022 21:34 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 100 | $154.77 | $15,477.00 |
DisclosureSEC source: 0001651308-22-000177 · wf-form4_166388243470166.xml · nonDerivative · entry 9 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F6 · security: Each American Depositary Share represents 13 Ordinary Shares. F7 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on March 7, 2022. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $154.69 to $154.85, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. F3 · ownership.nature: These securities are held by Oyler Investment LLC, of which 99% of the limited liability company interest is owned by a grantor retained annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership. Read SEC document |
| September 20, 2022 Filed Sep 22, 2022 21:34 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 5,411 | $153.81 | $832,242.64 |
DisclosureSEC source: 0001651308-22-000177 · wf-form4_166388243470166.xml · nonDerivative · entry 8 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 100 F6 · security: Each American Depositary Share represents 13 Ordinary Shares. F7 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on March 7, 2022. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.56 to $154.39, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. F3 · ownership.nature: These securities are held by Oyler Investment LLC, of which 99% of the limited liability company interest is owned by a grantor retained annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership. Read SEC document |
| September 20, 2022 Filed Sep 22, 2022 21:34 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 9,749 | $153.32 | $1,494,701.08 |
DisclosureSEC source: 0001651308-22-000177 · wf-form4_166388243470166.xml · nonDerivative · entry 7 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,511 F6 · security: Each American Depositary Share represents 13 Ordinary Shares. F7 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on March 7, 2022. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.56 to $153.55, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. F3 · ownership.nature: These securities are held by Oyler Investment LLC, of which 99% of the limited liability company interest is owned by a grantor retained annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 21:40 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 1,887,678 | $0.00 Strike: $11.98 | $0.00 |
DisclosureSEC source: 0001651308-22-000114 · wf-form4_165610682207683.xml · derivative · entry 7 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,887,678 Underlying: Ordinary Shares · 1,887,678 shares Expires 2032-06-21 F7 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F7 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F8 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on the first anniversary of June 22, 2022 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested shares are subject to accelerated vesting upon change of control or certain termination events. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 21:40 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantOrdinary Shares | 334,009 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-22-000114 · wf-form4_165610682207683.xml · nonDerivative · entry 1 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,070,913 F1 · security: Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 22, 2022, subject to continued service. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. Read SEC document |
| September 15, 2021 Filed Sep 16, 2021 22:06 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 200 | $383.00 | $76,600.00 |
DisclosureSEC source: 0001651308-21-000193 · wf-form4_163182994806480.xml · nonDerivative · entry 24 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2020. Read SEC document |
| September 15, 2021 Filed Sep 16, 2021 22:06 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 700 | $382.06 | $267,438.50 |
DisclosureSEC source: 0001651308-21-000193 · wf-form4_163182994806480.xml · nonDerivative · entry 23 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200 F1 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2020. F22 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $382.00 to $382.11, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| September 15, 2021 Filed Sep 16, 2021 22:06 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 2,000 | $379.81 | $759,616.00 |
DisclosureSEC source: 0001651308-21-000193 · wf-form4_163182994806480.xml · nonDerivative · entry 22 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900 F1 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2020. F21 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $379.54 to $380.08, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| September 15, 2021 Filed Sep 16, 2021 22:06 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 5,431 | $379.02 | $2,058,436.44 |
DisclosureSEC source: 0001651308-21-000193 · wf-form4_163182994806480.xml · nonDerivative · entry 21 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,900 F1 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2020. F20 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $378.52 to $379.42, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| September 15, 2021 Filed Sep 16, 2021 22:06 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 4,515 | $377.88 | $1,706,116.91 |
DisclosureSEC source: 0001651308-21-000193 · wf-form4_163182994806480.xml · nonDerivative · entry 20 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,331 F1 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2020. F19 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $377.29 to $378.27, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| September 15, 2021 Filed Sep 16, 2021 22:06 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 3,400 | $376.77 | $1,281,025.82 |
DisclosureSEC source: 0001651308-21-000193 · wf-form4_163182994806480.xml · nonDerivative · entry 19 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,846 F1 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2020. F18 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $376.15 to $377.03, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| September 15, 2021 Filed Sep 16, 2021 22:06 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 3,312 | $375.60 | $1,243,982.23 |
DisclosureSEC source: 0001651308-21-000193 · wf-form4_163182994806480.xml · nonDerivative · entry 18 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,246 F1 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2020. F17 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $375.02 to $376.00, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| September 15, 2021 Filed Sep 16, 2021 22:06 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 6,600 | $374.39 | $2,470,956.84 |
DisclosureSEC source: 0001651308-21-000193 · wf-form4_163182994806480.xml · nonDerivative · entry 17 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,558 F1 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2020. F16 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $374.00 to $374.995, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| September 15, 2021 Filed Sep 16, 2021 22:06 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleOrdinary Shares | 190,203 | $29.31 | $5,575,287.40 |
DisclosureSEC source: 0001651308-21-000193 · wf-form4_163182994806480.xml · nonDerivative · entry 2 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,736,904 F1 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2020. F3 · price: The price reported in Column 4 is a weighted average price per ordinary share. One ordinary share equals 1/13 American Depositary Share. These shares were sold in multiple transactions at prices ranging from $28.6685 to $29.5684, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of ordinary shares sold at each separate price. Read SEC document |
| September 14, 2021 Filed Sep 16, 2021 22:06 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 100 | $370.48 | $37,048.00 |
DisclosureSEC source: 0001651308-21-000193 · wf-form4_163182994806480.xml · nonDerivative · entry 16 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2020. Read SEC document |
| September 14, 2021 Filed Sep 16, 2021 22:06 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 1,100 | $369.65 | $406,615.00 |
DisclosureSEC source: 0001651308-21-000193 · wf-form4_163182994806480.xml · nonDerivative · entry 15 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 F1 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2020. F15 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $369.30 to $370.00, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| September 14, 2021 Filed Sep 16, 2021 22:06 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 10,989 | $368.51 | $4,049,501.45 |
DisclosureSEC source: 0001651308-21-000193 · wf-form4_163182994806480.xml · nonDerivative · entry 14 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,200 F1 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2020. F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $368.05 to $369.00, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| September 14, 2021 Filed Sep 16, 2021 22:06 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 4,759 | $367.52 | $1,749,035.77 |
DisclosureSEC source: 0001651308-21-000193 · wf-form4_163182994806480.xml · nonDerivative · entry 13 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,189 F1 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2020. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $367.03 to $368.02, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| September 14, 2021 Filed Sep 16, 2021 22:06 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 13,072 | $366.50 | $4,790,880.16 |
DisclosureSEC source: 0001651308-21-000193 · wf-form4_163182994806480.xml · nonDerivative · entry 12 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,948 F1 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2020. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $366.02 to $367.01, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.